Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change Price Change
grade A 133.68 0.64% 0.85
CELG closed up 0.64 percent on Thursday, June 22, 2017, on 2.21 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical CELG trend table...

Date Alert Name Type % Chg
Jun 22 New 52 Week High Bullish 0.00%
Jun 22 Upper Bollinger Band Walk Other 0.00%
Jun 22 Calm After Storm Range Contraction 0.00%
Jun 21 New 52 Week High Bullish 0.64%
Jun 21 Volume Surge Other 0.64%

Older signals for CELG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Is CELG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 135.18
52 Week Low 94.42
Average Volume 3,990,848
200-Day Moving Average 116.4254
50-Day Moving Average 121.013
20-Day Moving Average 120.3435
10-Day Moving Average 123.906
Average True Range 2.5667
ADX 31.41
+DI 48.98
-DI: 10.52
Chandelier Exit (Long, 3 ATRs) 127.4799
Chandelier Exit (Short, 3 ATRs) 121.3301
Upper Bollinger Band 130.7735
Lower Bollinger Band 109.9135
Percent B (%b) 1.14
Bandwidth 0.173337
MACD Line 2.6635
MACD Signal Line 0.8367
MACD Histogram 1.8268